Pfizer’s new heart drug isn’t all its cracked up to be. Marilynn Marchione of the Associated Press reports:Oh no, bad news. It’s a sad day for big pharma. It seems
Heart specialists have been anxious to know whether the problems extend to all such drugs and doom this approach.
"A lot of people think it's the next big thing, and we'll need to understand what went wrong with torcetrapib to move forward," said Dr. Steven Nissen, a Cleveland Clinic heart specialist who is president of the American College of Cardiology.
The new studies, reported at the group's conference, gave a mixed answer. The Pfizer drug seems uniquely risky, but other drugs have problems, too.
And even though they and the Pfizer drug raised HDL good cholesterol as intended, that made no difference in the odds of heart attacks or deaths, or key measures of cholesterol buildup in arteries.